- Home
- CLLS vs INGN Comparison
CLLS vs INGN Comparison
Compare CLLS & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- INGN
- Stock Information
- Founded
- CLLS 1999
- INGN 2001
- Country
- CLLS France
- INGN United States
- Employees
- CLLS N/A
- INGN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- INGN Industrial Specialties
- Sector
- CLLS Health Care
- INGN Health Care
- Exchange
- CLLS Nasdaq
- INGN Nasdaq
- Market Cap
- CLLS 240.2M
- INGN 260.2M
- IPO Year
- CLLS 2007
- INGN 2014
- Fundamental
- Price
- CLLS $2.01
- INGN $8.99
- Analyst Decision
- CLLS Buy
- INGN Hold
- Analyst Count
- CLLS 2
- INGN 4
- Target Price
- CLLS $8.00
- INGN $7.00
- AVG Volume (30 Days)
- CLLS 22.3K
- INGN 195.2K
- Earning Date
- CLLS 11-04-2024
- INGN 11-05-2024
- Dividend Yield
- CLLS N/A
- INGN N/A
- EPS Growth
- CLLS N/A
- INGN N/A
- EPS
- CLLS N/A
- INGN N/A
- Revenue
- CLLS $19,635,000.00
- INGN $326,653,000.00
- Revenue This Year
- CLLS $271.02
- INGN $5.76
- Revenue Next Year
- CLLS $33.48
- INGN $4.10
- P/E Ratio
- CLLS N/A
- INGN N/A
- Revenue Growth
- CLLS N/A
- INGN N/A
- 52 Week Low
- CLLS $0.96
- INGN $4.13
- 52 Week High
- CLLS $3.77
- INGN $13.33
- Technical
- Relative Strength Index (RSI)
- CLLS 41.74
- INGN 26.20
- Support Level
- CLLS $1.95
- INGN $8.85
- Resistance Level
- CLLS $2.06
- INGN $9.33
- Average True Range (ATR)
- CLLS 0.10
- INGN 0.39
- MACD
- CLLS -0.01
- INGN -0.06
- Stochastic Oscillator
- CLLS 33.33
- INGN 13.71
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About INGN Inogen Inc
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.